C4 Therapeutics, Inc. CCCC · Stock Open C4 Therapeutics, Inc. in new tab
C4 Therapeutics, Inc. Analysis (CCCC)
Is C4 Therapeutics, Inc. a good investment? C4 Therapeutics, Inc. (CCCC) is currently trading at 3.50 USD. Market analysts have a consensus price target of 13.33 USD. This suggests a potential upside from current levels.
Earnings Schedule: C4 Therapeutics, Inc. is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -1.04.
Investor FAQ
Does C4 Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is C4 Therapeutics, Inc.?
C4 Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -1.09.
Company Profile
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Community Discussion